



SASKATCHEWAN  
COLLEGE OF PHARMACY  
PROFESSIONALS

# MicroSCOPE

June 26, 2019

## In This Issue

Health Canada warns  
Canadians of potential  
cancer risk associated  
with gentian violet

PEBC Results - Techs FYI

Inducements and Incentives

SaskPain Spring  
Newsletter 2019

Increase Pharmacy Manager in  
Multiple Locations

Oxybutynin Misuse

---

## Continuing Education

### Building Recovery Capital in Canada Conference

September 20, 2019

[More info](#)

---

**For up-to-the-minute  
information, news and events,  
visit the homepage of the  
SCPP website:**  
[www.saskpharm.ca](http://www.saskpharm.ca)

## Health Canada warns Canadians of potential cancer risk associated with gentian violet

Health Canada has completed a safety review of human health products and veterinary drugs containing gentian violet and has found that exposure to these products may increase the risk of cancer. Given the seriousness of this risk, Health Canada is advising Canadians to stop using all human and veterinary drug products containing gentian violet.

Gentian violet is an antiseptic dye used to treat fungal infections. Products containing gentian violet have been used on the skin, on mucous membranes (inside the nose, mouth or vagina), on open wounds, or on the nipple of a nursing mother to treat oral thrush in infants.

Please see link below for more details on what to do:

[Cancer Risk Associated with Gentian Violet.](#)

---

## PEBC Results - Technicians

As a reminder to all pharmacy assistants pursuing pharmacy technician licensure, through either the bridging pathway or graduated from an accredited program prior to 2016, the registration deadline is December 31, 2019. This means that the PEBC Qualifying Exam, Structured Practical Skills Assessment (SPSA), Jurisprudence Exam and registration application all must be completed prior to this date.

For candidates still needing to complete the SPSA through Saskatchewan Polytechnic, registration closes September 16, 2019. The last opportunity to write the PEBC Qualifying Exam is September 7 and 8, 2019 and registration closed on June 7, 2019.

As SCPP is only able to offer a limited number of Jurisprudence Exam appointments per week, it is highly recommend that those who currently can book an appointment to write the exam, do so as soon as possible. It is anticipated that exam appointments for the remainder of the year will fill up quickly. Candidates who are an unable to obtain a Jurisprudence Exam appointment due to all exam sittings being booked up, candidates can submit

MicroSCOPE is published by the Saskatchewan College of Pharmacy Professionals (SCPP) and is emailed to all active members of the College. As the newsletter includes decisions on matters such as regulations, drug schedule changes, etc., SCPP expects all members are aware of these matters.

To download a PDF of this e-newsletter, click [here](#).

an appeal to Council requesting an extension to the December 31, 2019 deadline to allow them to write the Jurisprudence Exam in January 2020. **The deadline to submit all appeals will be November 15, 2019.**

---

## Inducement and Incentives

Council had begun to investigate the matter of inducements and incentives several years ago and was asked to stand aside by both British Columbia (BC) and Alberta as they became involved in legal challenges over their respective bans. BC and Alberta had different approaches with respect to their ban on inducements. BC created a bylaw a bylaw around harm reduction whereas Alberta focused on the code of ethics and standards.

The Supreme Court ruled in favour of both BC and Alberta. The final word came down mid-August 2018 with respect to Alberta's case.

As a result of both BC and Alberta completing and winning their legal cases, SCPP reopened the file on inducements and incentives at our Council meeting at the end of September 2018. Council provided direction to SCPP and consultation with our corporate solicitor began in October. After several meetings and research, a preliminary brief was presented at the February 2019 Council meeting. Council further contemplated the legal documents and considerations provided and directed SCPP to produce a draft set of bylaws for the May Council meeting. Draft bylaws were presented to Council for consideration in May and several more questions arose that require further clarification from our corporate solicitor. This is presently underway and an amended set of bylaws will be presented to Council at the September 26, 2019 meeting.

---

## SaskPain - Spring Newsletter

SaskPain is a grass-roots group of patient/family advocates, multidisciplinary clinicians, educators, researchers, and healthcare administrators. They identify and implement strategies to improve pain management in Saskatchewan.

Primary drivers of this work are:

- Knowledgeable and engaged healthcare providers
- Knowledgeable and engaged people with pain and their significant others
- Specialty services for pain assessment and management
- Infrastructures to support quality practice and training.

[Spring Newsletter](#)

---

# Increase in the Number of Pharmacists as Pharmacy Manager in Multiple Locations

The College wishes to remind members of SCPP Regulatory Bylaw section 11 of Part I.

## ***Pharmacy Manager***

***11. At the discretion of the Registrar, a licensed pharmacist may be named as pharmacy manager in more than one pharmacy.***

Going Forward:

- The College will be reviewing each pharmacy to determine who is the pharmacy manager of record.
- When a pharmacist is noted to be the pharmacy manager in more than one location they will be contacted by the College for more information.

No new permits wherein the pharmacist is already the pharmacy manager in another pharmacy will be approved without the review by the Registrar as per SCPP Regulatory Bylaw section 11 of Part I

---

## Oxybutynin Misuse

Healthcare professionals in Saskatchewan have seen increases in oxybutynin misuse. SCPP encourages you to review appropriate prescribing practices of oxybutynin and to briefly describe the manifestations and management of oxybutynin toxicity. Kindly make reference to newsletter below.

[Oxybutynin Misuse Newsletter](#)